---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017768"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:25:17.698515+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics prices $75M underwritten offering of common stock and pre-funded warrants

## Summary
- Offering: 12,285,056 common shares at $4.07/share and 6,142,656 pre-funded warrants at $4.0699 each.
- Gross proceeds ~$75M; net proceeds ~$70.2M after underwriting discounts and expenses.
- Closing expected May 7, 2024; Stifel is sole bookrunner.
- Proceeds to fund BLA resubmission and commercialization of pz-cel, plus working capital.
- New and existing investors participating include Adage Capital, Janus Henderson, Nantahala, Suvretta, Vivo Capital.

## SEC filing metadata
- accession: 0001493152-24-017768
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/0001493152-24-017768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017768
- JSON: https://secwatch.observer/filing/0001493152-24-017768.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017768.txt

## Key facts
- Material Agreements
  ABEONA THERAPEUTICS INC. entered into Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated valued at $70.2 million (effective 2024-05-03).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Stifel, Nicolaus & Company, Incorporated
  - Value: $70.2 million
  - Effective: 2024-05-03
  source text: On May 3, 2024, Abeona Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Underwriter”) relating to the issuance and sale of an aggregate of (a) 12,285,056 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 6,142,656 shares of the Company’s common stock (the “Pre-Funded Warrants”) in an underwritten offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/0001493152-24-017768-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.